Molecular Diagnostics as an Indispensable Tool for the Diagnosis of Infectious Diseases of Viral Origin and Global Impact

Rosas-Murrieta, Nora Hilda; Herrera‐Camacho, Irma; Peña, Lourdes Millán-Pérez; Sosa-Jurado, Francisca; Santos‐López, Gerardo; VerónicaVallejo-Ruíz,; Reyes‐Leyva, Julio

doi:10.5772/57581

Cited by 3 publications

(3 citation statements)

References 192 publications

(170 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Standard RT-PCR to detect the SH gene of mumps virus can be used to detect mumps RNA in clinical samples or in infected cell culture [170]. The sequence of the PCR product containing the coding region of the SH gene can be used to determine the viral genotype [171]. A multiplex real-time RT-PCR test for the detection of RNA from mumps virus in patient specimens, using primers and probes that target the mumps SH gene [172].…”

Section: Mumps Virusmentioning

confidence: 99%

Trends in Infectious Diseases

Saxena¹

2014

View full text Add to dashboard Cite

is a Medical Microbiologist at CSIR-Centre for Cellular and Molecular Biology (CCMB) in India. The main research interests of his group are to understand the epidemiology and molecular mechanisms of host-defense during human viral infections and to develop new predictive, preventive and therapeutic strategies for them using JEV and HIV as a model. His research work has been published in various high impact factor journals with high citation. He has received many awards and honors in India and abroad including various Young Scientist Awards, BBSRC India Partnering Award and named as "Global Leader in Science" by The Scientist magazine (USA).

show abstract

Section: Mumps Virusmentioning

confidence: 99%

Trends in Infectious Diseases

Saxena¹

2014

View full text Add to dashboard Cite

show abstract

“…Influenza A virus is a viral pathogen associated with high morbidity and mortality rates, and it causes several epidemics and pandemics every year worldwide, especially in the winter season [1,2] The annual epidemics caused by influenza A can be attributed to major mutations in the HA and NA glycoproteins [3][4][5]. Unlike mutations in HA and NA, the M protein on the surface of influenza A virus is the most conserved structural protein and is similar among influenza A virus species [6].…”

Section: Introductionmentioning

confidence: 99%

Application of an immunoglobulin Y-alkaline phosphatase bioconjugate as a diagnostic tool for influenza A virus

et al. 2019

View full text Add to dashboard Cite

The diagnosis of influenza A virus is essential since it can be confused with influenza A like illness and lead to inaccurate drug prescription. In this study, the M2e peptide, a strategic antigen that is conserved in all virus subtypes, was used as a diagnostic marker of influenza A. For the first time, M2e-specific IgY antibody was covalently conjugated to alkaline phosphatase (ALP) enzyme in the presence of glutaraldehyde. The antibody-enzyme bioconjugate was characterized by fluorescence and Fourier-transform infrared spectroscopy. Subsequently, the diagnostic value of this bioconjugate was evaluated by direct sandwich ELISA using nasopharyngeal swab samples positive/negative for H1N1 and H3N2, which were previously analyzed by rRT-PCR for influenza. In conclusion, the M2e-specific IgY-ALP bioconjugate demonstrated positive results for Influenza A in samples that were diagnosed as Influenza A via the RT-PCR method. ARTICLE HISTORY

show abstract

“…Viruses can be also detected using viral genomic DNA and genomic, messenger and micro RNA. 27 Recently, FDA has approved several assays and platforms for detection of genomic and messenger viral RNA, summarized in Table I. 26,[28][29][30][31][32][33][34] These platforms offer a limit of detection (LOD) of 10-200 copies/ml, and linear quantification up to 10 À8 copies/ml.…”

Section: Fda-approved Rna Assays and Platformsmentioning

confidence: 99%

Future microfluidic and nanofluidic modular platforms for nucleic acid liquid biopsy in precision medicine

et al. 2016

View full text Add to dashboard Cite

Nucleic acid biomarkers have enormous potential in non-invasive diagnostics and disease management. In medical research and in the near future in the clinics, there is a great demand for accurate miRNA, mRNA, and ctDNA identification and profiling. They may lead to screening of early stage cancer that is not detectable by tissue biopsy or imaging. Moreover, because their cost is low and they are non-invasive, they can become a regular screening test during annual checkups or allow a dynamic treatment program that adjusts its drug and dosage frequently. We briefly review a few existing viral and endogenous RNA assays that have been approved by the Federal Drug Administration. These tests are based on the main nucleic acid detection technologies, namely, quantitative reverse transcription polymerase chain reaction (PCR), microarrays, and next-generation sequencing. Several of the challenges that these three technologies still face regarding the quantitative measurement of a panel of nucleic acids are outlined. Finally, we review a cluster of microfluidic technologies from our group with potential for point-of-care nucleic acid quantification without nucleic acid amplification, designed to overcome specific limitations of current technologies. We suggest that integration of these technologies in a modular design can offer a low-cost, robust, and yet sensitive/selective platform for a variety of precision medicine applications.

show abstract

Molecular Diagnostics as an Indispensable Tool for the Diagnosis of Infectious Diseases of Viral Origin and Global Impact

Cited by 3 publications

References 192 publications

Trends in Infectious Diseases

Trends in Infectious Diseases

Application of an immunoglobulin Y-alkaline phosphatase bioconjugate as a diagnostic tool for influenza A virus

Future microfluidic and nanofluidic modular platforms for nucleic acid liquid biopsy in precision medicine

Contact Info

Product

Resources

About